Sandra Calvin, VP, Corporate Controller and CAO at Travere Therapeutics, Inc. (TVTX), sold 798 shares at $26.51 ($21K) on 2022-01-31, disclosed to the SEC on 2022-02-02.
Open-market sale of $21k TVTX by VP, Corporate Controller and CAO. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| Filing → |
| TVTX | SELL | 2026-02-03 | $139K | — | Filing → |
| TVTX | SELL | 2025-12-29 | $296K | — | Filing → |
| TVTX | SELL | 2025-12-16 | $105K | — | Filing → |